Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

Merck Life Science South Africa, a leading science and technology company, is excited to announce its participation as a bronze sponsor at Analytica Lab Africa 2025. This major trade fair for ...